CorMedix Free Cash Flow Yield vs Days Sales Outstanding Analysis
| CRMD Stock | USD 9.96 0.37 3.58% |
CorMedix financial indicator trend analysis is way more than just evaluating CorMedix prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether CorMedix is a good investment. Please check the relationship between CorMedix Free Cash Flow Yield and its Days Sales Outstanding accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CorMedix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade CorMedix Stock refer to our How to Trade CorMedix Stock guide.
Free Cash Flow Yield vs Days Sales Outstanding
Free Cash Flow Yield vs Days Sales Outstanding Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of CorMedix Free Cash Flow Yield account and Days Sales Outstanding. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between CorMedix's Free Cash Flow Yield and Days Sales Outstanding is -0.35. Overlapping area represents the amount of variation of Free Cash Flow Yield that can explain the historical movement of Days Sales Outstanding in the same time period over historical financial statements of CorMedix, assuming nothing else is changed. The correlation between historical values of CorMedix's Free Cash Flow Yield and Days Sales Outstanding is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Yield of CorMedix are associated (or correlated) with its Days Sales Outstanding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Days Sales Outstanding has no effect on the direction of Free Cash Flow Yield i.e., CorMedix's Free Cash Flow Yield and Days Sales Outstanding go up and down completely randomly.
Correlation Coefficient | -0.35 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Free Cash Flow Yield
A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.Days Sales Outstanding
Most indicators from CorMedix's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into CorMedix current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CorMedix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade CorMedix Stock refer to our How to Trade CorMedix Stock guide.At present, CorMedix's Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 155.8 M, whereas Sales General And Administrative To Revenue is forecasted to decline to 20.53.
| 2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 177.0K | 209.0K | 70.8K | 79.6K | Research Development | 13.1M | 10.7M | 13.2M | 10.2M |
CorMedix fundamental ratios Correlations
Click cells to compare fundamentals
CorMedix Account Relationship Matchups
High Positive Relationship
High Negative Relationship
CorMedix fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 29.5M | 49.3M | 68.9M | 62.0M | 82.1M | 86.2M | |
| Other Current Liab | 4.8M | 2.9M | 3.0M | 4.0M | 7.0M | 7.3M | |
| Total Current Liabilities | 5.8M | 4.2M | 5.3M | 6.3M | 11.4M | 12.0M | |
| Accounts Payable | 1.0M | 1.1M | 2.2M | 2.2M | 4.3M | 4.5M | |
| Cash | 16.5M | 42.1M | 53.6M | 43.4M | 43.6M | 45.8M | |
| Other Current Assets | 501.2K | 1.7M | 954.0K | 758.8K | 1.3M | 725.0K | |
| Total Liab | 5.8M | 5.1M | 6.1M | 7.0M | 11.9M | 7.3M | |
| Common Stock | 25.7K | 33.6K | 38.1K | 42.8K | 54.9K | 36.3K | |
| Property Plant Equipment | 126.8K | 1.1M | 1.5M | 2.4M | 2.7M | 2.9M | |
| Short Long Term Debt Total | 2.7K | 1.0M | 923.8K | 802.4K | 667.6K | 634.3K | |
| Total Stockholder Equity | (195.4M) | (217.4M) | (245.7M) | (275.4M) | 70.1M | 73.6M | |
| Property Plant And Equipment Net | 126.8K | 1.1M | 2.4M | 2.4M | 2.5M | 2.6M | |
| Net Debt | (16.5M) | (41.1M) | (52.6M) | (42.6M) | (43.0M) | (40.8M) | |
| Retained Earnings | (195.4M) | (217.4M) | (245.7M) | (275.4M) | (321.7M) | (305.6M) | |
| Non Current Assets Total | 126.8K | 1.1M | 2.5M | 2.5M | 2.6M | 2.7M | |
| Non Currrent Assets Other | 126.8K | (1.1M) | 102.3K | 102.3K | 103.1K | 108.2K | |
| Cash And Short Term Investments | 28.5M | 46.5M | 65.7M | 59.0M | 76.0M | 79.8M | |
| Common Stock Total Equity | 108.9K | 25.7K | 33.6K | 38.1K | 43.8K | 36.2K | |
| Common Stock Shares Outstanding | 24.2M | 28.6M | 37.7M | 40.3M | 50.9M | 53.4M | |
| Liabilities And Stockholders Equity | (189.6M) | (212.4M) | (239.5M) | (268.4M) | 82.1M | 86.2M | |
| Other Stockholder Equity | (123.2K) | 261.5M | 308.3M | 330.3M | 391.7M | 411.3M | |
| Property Plant And Equipment Gross | 126.8K | 1.1M | 2.7M | 2.8M | 3.0M | 3.2M | |
| Total Current Assets | 29.3M | 48.2M | 66.5M | 59.6M | 79.5M | 83.4M | |
| Accumulated Other Comprehensive Income | 97.3K | 102.0K | 87.1K | 82.7K | 94.1K | 56.5K | |
| Non Current Liabilities Total | 2.7K | 923.7K | 802.4K | 667.6K | 517.0K | 491.2K | |
| Net Tangible Assets | 23.6M | 44.2M | 62.8M | 55.1M | 63.3M | 66.5M | |
| Net Receivables | 64.1K | 10.9K | 35.0 | 3.4K | 45.4K | 0.0 | |
| Retained Earnings Total Equity | (179.0M) | (195.4M) | (217.4M) | (245.7M) | (221.1M) | (210.0M) | |
| Short Term Investments | 12.0M | 4.4M | 12.1M | 15.6M | 32.4M | 34.0M | |
| Capital Surpluse | 183.7M | 218.9M | 261.5M | 308.3M | 354.6M | 372.3M | |
| Inventory | 428.5K | 338.5K | 143.6K | 3.0K | 2.1M | 2.2M | |
| Net Invested Capital | 23.6M | 44.2M | 62.8M | 55.1M | 70.1M | 43.1M | |
| Net Working Capital | 23.5M | 44.0M | 61.1M | 53.2M | 68.0M | 42.1M | |
| Capital Stock | 25.9K | 33.8K | 38.3K | 43.0K | 55.1K | 40.7K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether CorMedix is a strong investment it is important to analyze CorMedix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CorMedix's future performance. For an informed investment choice regarding CorMedix Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CorMedix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade CorMedix Stock refer to our How to Trade CorMedix Stock guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CorMedix. If investors know CorMedix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CorMedix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.80) | Revenue Per Share 0.212 | Quarterly Revenue Growth (0.47) | Return On Assets (0.38) | Return On Equity (0.65) |
The market value of CorMedix is measured differently than its book value, which is the value of CorMedix that is recorded on the company's balance sheet. Investors also form their own opinion of CorMedix's value that differs from its market value or its book value, called intrinsic value, which is CorMedix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CorMedix's market value can be influenced by many factors that don't directly affect CorMedix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CorMedix's value and its price as these two are different measures arrived at by different means. Investors typically determine if CorMedix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CorMedix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.